{"version":"1.0","type":"link","title":"SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?","author_name":"Haddad FG 외","author_url":"https://prs-insight.online/author/Haddad%20FG","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/85935","thumbnail_width":1200,"thumbnail_height":630}